In 2019, Kopp L.M. et al. reported a single-arm phase 2 clinical trial which explored the anti-tumor activity of glembatumumab vedotin (an ADC against GPNMB) in patients with recurrent or refractory osteosarcoma [33]. This evidence concerns the gene GPNMB and osteosarcoma.